Serum Interferon Gamma-induced Protein 10 Levels in Patients with Type 2 Diabetes and Metabolic Dysfunction-associated Steatotic Liver Disease: A Case-control Study.
- 1Department of Endocrinology and Metabolism, Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt.
- 2Department of Hepatogastroenterology and Infectious Diseases, Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt.
- 3Department of Biochemistry and Molecular Biology, Faculty of Pharmacy for Boys, Al-Azhar University, Cairo, Egypt.
Abstract
Background
Metabolic dysfunction-associated steatotic liver disease (MASLD) is linked to type 2 diabetes mellitus (T2D), with insulin resistance, dyslipidemia, and inflammation contributing to disease progression. Interferon-γ-inducible protein-10 (IP-10) is a proinflammatory chemokine implicated in hepatic inflammation and metabolic dysfunction.Objectives
To assess circulating IP-10 levels in patients with concomitant T2D and MASLD, examine their associations with metabolic and hepatic parameters, and evaluate their discriminatory performance.Methods
This case-control study included 120 adults (60 patients with T2D and MASLD, and 60 age- and sex-matched healthy controls). Hepatic steatosis and fibrosis were evaluated using ultrasonography, transient elastography (FibroScan®), hepatic steatosis index, and FIB-4 score. Serum IP-10 levels were measured using ELISA and its discriminatory performance was assessed using receiver operating characteristic (ROC) curve analysis.Results
Serum IP-10 was significantly higher in patients with T2D and MASLD compared with controls. Serum IP-10 showed significant positive correlations with LDL-C, HbA1c, HOMA-IR, FIB-4 score, and liver stiffness measurements, while remaining unrelated to steatosis grade or BMI. ROC curve analysis demonstrated excellent discriminatory performance of IP-10 between patients with T2D and MASLD and metabolically healthy controls, with an AUC of 0.97 at a cut-off value >940 pg/mL, yielding 85.0% sensitivity and 96.7% specificity.Conclusion
Serum IP-10 is significantly elevated in patients with MASLD and T2D and correlates with key markers of metabolic dysfunction and hepatic fibrosis. IP-10 demonstrates excellent discriminatory ability between patients with combined T2D and MASLD and metabolically healthy controls, supporting its potential relevance as a non-invasive biomarker in this metabolic phenotype.
Related
- Efficacy and safety of GLP-1 receptor agonists in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) : A systematic review and meta-analysis
- Dose-dependent efficacy and renal safety of pemafibrate versus fenofibrate in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and hypertriglyceridemia: a multicenter randomized controlled, open label trial
- Factors associated with significant liver fibrosis in patients with type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease: a single-center retrospective study
- METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: ASSOCIATION WITH BODY MASS INDEX AND DISEASE SEVERITY
- Effects of Whole “Navelina” Orange Consumption on Glucose Homeostasis and Fructosamine Levels in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Randomized Controlled Trial
BibTeX
@article{bashir2026serum,
title = {{Serum Interferon Gamma-induced Protein 10 Levels in Patients with Type 2 Diabetes and Metabolic Dysfunction-associated Steatotic Liver Disease: A Case-control Study.}},
author = {Nahla Bashir and Olfat Fawzy and Sally Abd El-Aziz and Moshira A Ibrahim and Emad G Khidr},
journal = {Saudi journal of medicine \& medical sciences},
year = {2026},
month = oct,
doi = {10.4103/sjmms.sjmms_438_26},
url = {https://europepmc.org/article/MED/42974313},
note = {CC BY-NC-SA},
}
RIS
TY - JOUR
TI - Serum Interferon Gamma-induced Protein 10 Levels in Patients with Type 2 Diabetes and Metabolic Dysfunction-associated Steatotic Liver Disease: A Case-control Study.
AU - Nahla Bashir
AU - Olfat Fawzy
AU - Sally Abd El-Aziz
AU - Moshira A Ibrahim
AU - Emad G Khidr
PY - 2026
DA - 2026/10/14
JO - Saudi journal of medicine & medical sciences
DO - 10.4103/sjmms.sjmms_438_26
UR - https://europepmc.org/article/MED/42974313
AB - Background Metabolic dysfunction-associated steatotic liver disease (MASLD) is linked to type 2 diabetes mellitus (T2D), with insulin resistance, dyslipidemia, and inflammation contributing to disease progression. Interferon-γ-inducible protein-10 (IP-10) is a proinflammatory chemokine implicated in hepatic inflammation and metabolic dysfunction.Objectives To assess circulating IP-10 levels in patients with concomitant T2D and MASLD, examine their associations with metabolic and hepatic parameters, and evaluate their discriminatory performance.Methods This case-control study included 120 adults (60 patients with T2D and MASLD, and 60 age- and sex-matched healthy controls). Hepatic steatosis and fibrosis were evaluated using ultrasonography, transient elastography (FibroScan®), hepatic steatosis index, and FIB-4 score. Serum IP-10 levels were measured using ELISA and its discriminatory performance was assessed using receiver operating characteristic (ROC) curve analysis.Results Serum IP-10 was significantly higher in patients with T2D and MASLD compared with controls. Serum IP-10 showed significant positive correlations with LDL-C, HbA1c, HOMA-IR, FIB-4 score, and liver stiffness measurements, while remaining unrelated to steatosis grade or BMI. ROC curve analysis demonstrated excellent discriminatory performance of IP-10 between patients with T2D and MASLD and metabolically healthy controls, with an AUC of 0.97 at a cut-off value >940 pg/mL, yielding 85.0% sensitivity and 96.7% specificity.Conclusion Serum IP-10 is significantly elevated in patients with MASLD and T2D and correlates with key markers of metabolic dysfunction and hepatic fibrosis. IP-10 demonstrates excellent discriminatory ability between patients with combined T2D and MASLD and metabolically healthy controls, supporting its potential relevance as a non-invasive biomarker in this metabolic phenotype.
SN - 1658-631X
SN - 2321-4856
ER -